Business
Therapeutics Sector Shows Resilience in Q3: United Therapeutics Lags as Halozyme and Biogen Outperform
A mixed third-quarter earnings season for therapeutics stocks reveals divergent paths, with United Therapeutics missing estimates while peers like Halozyme and Biogen post strong beats. Sector-wide revenue growth and positive stock reactions suggest underlying investor confidence despite regulatory and pricing headwinds.